Ketamine and Your Gut: The Microbiome Connection

When people think about ketamine therapy, they think about the brain — NMDA receptors, glutamate, neuroplasticity. But a growing body of research suggests that the gut may play a surprisingly important role in how ketamine exerts its antidepressant effects. A 2025 review published by Springer examining ketamine enantiomers and gut microbiota reveals a bidirectional relationship that could reshape how we understand and optimize ketamine treatment.

The Gut-Brain Axis, Briefly

The gut-brain axis is the communication network linking your gastrointestinal tract and your central nervous system. It operates through multiple channels: the vagus nerve, immune signaling molecules, hormonal pathways, and metabolites produced by the trillions of bacteria living in your gut — collectively known as the gut microbiome.

This is not a fringe concept. Research over the past decade has established that gut microbiome composition is associated with depression, anxiety, and stress responses. Patients with major depressive disorder show measurably different gut bacteria profiles compared to healthy controls. The question that researchers are now asking is whether ketamine's therapeutic effects involve changes to this microbial ecosystem.

How Ketamine Affects the Gut Microbiome

The 2025 Springer review synthesized preclinical and clinical evidence showing that ketamine administration alters gut microbiome composition. In animal models of depression, ketamine treatment shifted microbial populations toward profiles associated with healthier mood states. These changes were not incidental — they correlated with behavioral improvements and neurobiological markers of antidepressant response.

Several mechanisms appear to be at play. Ketamine reduces levels of pro-inflammatory cytokines, including IL-1 beta, IL-6, and TNF-alpha. These inflammatory molecules are overproduced in depression and are known to disrupt gut barrier integrity and alter microbial populations. By reducing systemic inflammation, ketamine may create a more favorable environment for beneficial gut bacteria.

Additionally, ketamine increases production of brain-derived neurotrophic factor (BDNF), a protein critical for neuroplasticity and neuronal survival. Emerging evidence suggests that certain gut bacteria contribute to BDNF production through their metabolites, particularly short-chain fatty acids. This creates a potential feedback loop: ketamine boosts BDNF directly through central mechanisms, and the resulting shifts in gut microbiome composition may further support BDNF production from the periphery.

For more on ketamine's relationship with BDNF, see our article on ketamine, BDNF, and neuroplasticity.

S-Ketamine vs R-Ketamine: Different Gut Effects

One of the more intriguing findings from the review concerns the two mirror-image forms (enantiomers) of ketamine: S-ketamine and R-ketamine. These two molecules have the same chemical formula but differ in their three-dimensional structure, and they appear to affect the gut microbiome differently.

S-ketamine — the form used in the FDA-approved nasal spray Spravato — and R-ketamine show distinct patterns of microbiome modulation in preclinical studies. R-ketamine, in particular, has shown more sustained antidepressant effects in animal models, and some researchers hypothesize that its unique impact on gut microbial composition may contribute to this difference.

The racemic ketamine used in most oral formulations (including the sublingual troches prescribed through Isha Health) contains both S- and R-ketamine in equal proportions. This means patients receiving racemic ketamine may benefit from the complementary gut microbiome effects of both enantiomers.

How Gut Health Might Influence Your Response to Ketamine

The bidirectional nature of the ketamine-microbiome relationship raises a practical question: could the state of your gut health influence how well ketamine therapy works for you?

While definitive clinical trials have not yet been conducted on this specific question, the mechanistic evidence is suggestive. If gut bacteria contribute to inflammation levels, BDNF production, and neurotransmitter precursor metabolism, then the composition of a patient's microbiome at baseline could theoretically affect their response to ketamine.

This does not mean you need to overhaul your diet before starting ketamine therapy. But it does suggest that general gut health practices may complement treatment:

• Dietary fiber: Fruits, vegetables, and whole grains feed beneficial gut bacteria that produce anti-inflammatory short-chain fatty acids
• Fermented foods: Yogurt, kimchi, sauerkraut, and kefir introduce beneficial bacterial strains
• Probiotic supplements: Certain strains, particularly Lactobacillus and Bifidobacterium species, have shown mood-related benefits in clinical studies
• Limiting processed foods: Highly processed diets are associated with reduced microbial diversity and increased gut inflammation

These recommendations are consistent with general health guidance and pose no risk when combined with ketamine therapy.

The Bigger Picture: Ketamine as an Anti-Inflammatory

The gut microbiome connection fits within a larger narrative about ketamine's anti-inflammatory properties. Depression is increasingly understood as a condition with significant inflammatory components, and ketamine's ability to reduce neuroinflammation is likely a key part of its therapeutic mechanism. For a deeper dive into this topic, see our article on ketamine, neuroinflammation, and anti-inflammatory effects.

The gut-brain axis research adds a new dimension to this story. Ketamine may not only reduce inflammation directly through central mechanisms but also indirectly through its effects on the gut microbiome — which itself is a major regulator of systemic inflammation.

What This Means for Patients

This research is still in relatively early stages, and clinical recommendations specific to optimizing gut health for ketamine response have not yet been established. However, the science is pointing toward an integrated view of ketamine therapy — one where the drug's effects extend beyond the brain to encompass the gut-brain axis.

For patients currently receiving or considering ketamine therapy, this is an area worth watching. Review Isha Health's clinical outcomes and explore our online ketamine therapy program to learn more about our approach.

---

Related Articles

• Ketamine, BDNF, and Neuroplasticity
• Ketamine and Neuroinflammation
• What Supplements to Take with Ketamine Therapy

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.